Condition: Urothelial Carcinoma Bladder · Bladder Cancer · Sponsor: Abramson Cancer Center at Penn Medicine
The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.
This description comes directly from the study's public registry record.
Project Manager · 215-662-3790 · RadOncCRU@PennMedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06586255